Hugel Inc (145020) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hugel Inc (145020) has a cash flow conversion efficiency ratio of 0.056x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩57.43 Billion ≈ $38.92 Million USD) by net assets (₩1.03 Trillion ≈ $701.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 145020 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Hugel Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Hugel Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hugel Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hugel Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dalian Zeus Entertainment
SHE:002354
|
-0.005x |
|
Guangdong Advertising Co Ltd
SHE:002400
|
0.025x |
|
Omnicell Inc
NASDAQ:OMCL
|
0.025x |
|
Westshore Terminals Investment Corp
TO:WTE
|
0.127x |
|
Megaport Ltd
AU:MP1
|
0.069x |
|
BIEM.L .FDLKK Garment Co Ltd
SHE:002832
|
0.029x |
|
Fagron NV
BR:FAGR
|
0.167x |
|
4iG Nyrt.
BUD:4IG
|
0.147x |
Annual Cash Flow Conversion Efficiency for Hugel Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Hugel Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Hugel Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩980.16 Billion ≈ $664.24 Million |
₩150.06 Billion ≈ $101.69 Million |
0.153x | -13.64% |
| 2024-12-31 | ₩840.81 Billion ≈ $569.81 Million |
₩149.05 Billion ≈ $101.01 Million |
0.177x | +17.42% |
| 2023-12-31 | ₩779.68 Billion ≈ $528.38 Million |
₩117.71 Billion ≈ $79.77 Million |
0.151x | +48.32% |
| 2022-12-31 | ₩792.11 Billion ≈ $536.80 Million |
₩80.63 Billion ≈ $54.64 Million |
0.102x | -7.96% |
| 2021-12-31 | ₩777.09 Billion ≈ $526.62 Million |
₩85.94 Billion ≈ $58.24 Million |
0.111x | +11.14% |
| 2020-12-31 | ₩746.67 Billion ≈ $506.01 Million |
₩74.30 Billion ≈ $50.35 Million |
0.100x | -9.59% |
| 2019-12-31 | ₩699.50 Billion ≈ $474.04 Million |
₩76.99 Billion ≈ $52.18 Million |
0.110x | +21.74% |
| 2018-12-31 | ₩727.72 Billion ≈ $493.17 Million |
₩65.80 Billion ≈ $44.59 Million |
0.090x | -2.01% |
| 2017-12-31 | ₩695.71 Billion ≈ $471.47 Million |
₩64.19 Billion ≈ $43.50 Million |
0.092x | -48.33% |
| 2016-12-31 | ₩252.80 Billion ≈ $171.32 Million |
₩45.14 Billion ≈ $30.59 Million |
0.179x | +87.79% |
| 2015-12-31 | ₩207.85 Billion ≈ $140.85 Million |
₩19.76 Billion ≈ $13.39 Million |
0.095x | -52.12% |
| 2014-12-31 | ₩53.21 Billion ≈ $36.06 Million |
₩10.57 Billion ≈ $7.16 Million |
0.199x | -- |
About Hugel Inc
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more